

# NCIC CLINICAL TRIALS GROUP

## GENITOURINARY

### DISEASE SITE COMMITTEE MEETING AGENDA

DELTA CHELSEA HOTEL, TORONTO, ON

ROOM: Wren

APRIL 28, 2012 – 9:10 AM – 03:30 PM

CHAIR: F. SAAD

(03:30 PM – 04:30 PM EXECUTIVE COMMITTEE MEETING – CLOSED)

#### **CME Credits:**

*Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.*

#### **Learning Objectives:**

- To understand and address, through clinical and translational research, the disease burden associated with genitourinary malignancies in Canada.
- To review recent developments in the understanding of molecular biology and new therapeutics as these relate to genitourinary malignancies.
- To update, review, and discuss recent results of clinical studies conducted by or in collaboration with NCIC Clinical Trials Group.
- To provide a learning environment supportive to new investigators.
- To understand and apply new clinical trial methodologies in the field of clinical research related to genitourinary malignancies.

---

<b>9:10 am</b>	<b>WELCOME AND APPROVAL OF PREVIOUS MINUTES</b>	F. Saad
<b>9:15 am</b>	<b>NCIC CTG/INTERGROUP PHASE III TRIALS: OPEN</b>	
	PR.13 (RADICALS)/MRC PR.10	C. Catton/F. Saad
<b>9:30 am</b>	<b>NCIC CTG/INTERGROUP PHASE III TRIALS: CLOSED. PENDING ANALYSES</b>	
	PR.11	F. Saad
	BL 8/EORTC 30994	F. Saad
	REC.2/ECOG E2805 Sunitinib/placebo vs. Sorafenib/placebo vs. placebo in resected RCC	J. Knox
<b>9:45 am</b>	<b>COFFEE BREAK</b>	

*continued on next page ...*

- 10:00 am NCIC CTG PHASE III TRIALS: RECENT ANALYSES**
- PR.3 – Final analysis P. Warde/ M. Brundage  
 PR.8/SWOG 9346 B. Donnelly
- 10:40 am NCIC CTG/INTERGROUP PHASE III TRIALS: PUBLICATIONS**
- BL.7 E. Winquist
- 10:50 am CTSU TRIALS ACTIVATED BY NCIC CTG: OPEN**
- PRC.2/CALGB 90202 Early vs. Standard Zoledronic Acid  
 in CaP metastatic to bone F. Saad  
 PRC.3/CALGB 90203 Neoadjuvant Docetaxel plus Androgen  
 Deprivation prior to RP v.s. RP only F. Saad
- 11:10 am NCIC CTG IND TRIALS**
- IND.195: A Phase II Study of SB 939 in Patients with CRPC K. Chi  
 IND.205: PX-866 in recurrent or metastatic CRPC S. Hotte  
 IND.209: Reolysin in combination with docetaxel and prednisone  
 or docetaxel and prednisone alone in metastatic CRPC K. Chi
- 11:30 am UPDATE ON NCIC CTG APPROVED STUDIES**
- Pilot Study of HDR Brachytherapy in Intermediate Risk CaP E. Vigneault/ A. Loblaw
- 11:45 am OPEN CUOG TRIALS**
- 12:15 pm Lunch**
- 1:30 pm UPDATE ON CLOSED CUOG TRIALS**
- 2:00 pm New study proposals**
- A Phase III Randomized trial of Nab-Paclitaxel vs. Paclitaxel in  
 Second Line Metastatic Urothelial Carcinoma K. Sridhar  
 Systemic Therapy in Advancing or Metastatic Prostate cancer. STAMPEDE K. Chi  
 Abiraterone in CRPC K. Chi
- 3:00 pm DOG REPORTS**
- Localized Prostate Cancer A. Loblaw/ N. Fleshner  
 Advanced Prostate Cancer K. Chi/ F. Saad  
 Advanced Bladder S. North/W. Kassouf  
 Renal J. Knox/ A. Kapoor  
 Testes C. Kollmaannsberger/ P. Chung  
 Superficial bladder A. So
- 3:30 pm Meeting Adjourned, EXECUTIVE COMMITTEE MEETING TO FOLLOW (CLOSED)**